Compugen Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGEN research report →
Companycgen.com
Compugen Ltd. , a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- CEO
- Eran Ophir
- IPO
- 2000
- Employees
- 74
- HQ
- Holon, IL
Price Chart
Valuation
- Market Cap
- $255.77M
- P/E
- 7.34
- P/S
- 3.52
- P/B
- 2.68
- EV/EBITDA
- 7.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 88.06%
- Op Margin
- 42.26%
- Net Margin
- 47.97%
- ROE
- 47.72%
- ROIC
- 24.67%
Growth & Income
- Revenue
- $72.76M · 161.14%
- Net Income
- $35.34M · 348.35%
- EPS
- $0.38 · 337.50%
- Op Income
- $31.33M
- FCF YoY
- -36.69%
Performance & Tape
- 52W High
- $3.24
- 52W Low
- $1.30
- 50D MA
- $2.54
- 200D MA
- $1.88
- Beta
- 2.80
- Avg Volume
- 453.26K
Get TickerSpark's AI analysis on CGEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | Levine Zurit | other | 2,000 |
| Apr 24, 26 | Levine Zurit | other | 2,000 |
| Apr 24, 26 | Levine Zurit | sell | 2,000 |
| Apr 24, 26 | Ophir Eran | other | 5,000 |
| Apr 24, 26 | Ophir Eran | other | 5,000 |
| Apr 24, 26 | Ophir Eran | sell | 5,000 |
| Apr 14, 26 | Ophir Eran | other | 5,000 |
| Apr 14, 26 | Ophir Eran | other | 5,000 |
| Apr 14, 26 | Ophir Eran | sell | 5,000 |
| Apr 14, 26 | Levine Zurit | other | 2,000 |
Our CGEN Coverage
We haven't published any research on CGEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CGEN Report →